Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.
Saved in:
| Title: | Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. |
|---|---|
| Authors: | Chang WH; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Vaughan AJ; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York., Stamey AG; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Mancini M; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.; Department of Biochemistry, Federal University of São Paulo, São Paulo, Brazil., Hayashi M; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York., Yang R; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Robb R; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Andrussier D; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York., Klomp JA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Waters AM; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Schaefer A; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Bryant KL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Cox AD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Simabuco FM; Department of Biochemistry, Federal University of São Paulo, São Paulo, Brazil., Wong KK; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Stalnecker CA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Papagiannakopoulos T; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York., Der CJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. |
| Source: | BioRxiv : the preprint server for biology [bioRxiv] 2026 Apr 21. Date of Electronic Publication: 2026 Apr 21. |
| Publication Type: | Journal Article; Preprint |
| Journal Info: | Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42079131 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Chang+WH%22">Chang WH</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Vaughan+AJ%22">Vaughan AJ</searchLink>; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.<br /><searchLink fieldCode="AU" term="%22Stamey+AG%22">Stamey AG</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Mancini+M%22">Mancini M</searchLink>; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.; Department of Biochemistry, Federal University of São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Hayashi+M%22">Hayashi M</searchLink>; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.<br /><searchLink fieldCode="AU" term="%22Yang+R%22">Yang R</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Robb+R%22">Robb R</searchLink>; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Andrussier+D%22">Andrussier D</searchLink>; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.<br /><searchLink fieldCode="AU" term="%22Klomp+JA%22">Klomp JA</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Waters+AM%22">Waters AM</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Schaefer+A%22">Schaefer A</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Wolpin+BM%22">Wolpin BM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Bryant+KL%22">Bryant KL</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Cox+AD%22">Cox AD</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Simabuco+FM%22">Simabuco FM</searchLink>; Department of Biochemistry, Federal University of São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Wong+KK%22">Wong KK</searchLink>; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.<br /><searchLink fieldCode="AU" term="%22Aguirre+AJ%22">Aguirre AJ</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Stalnecker+CA%22">Stalnecker CA</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.<br /><searchLink fieldCode="AU" term="%22Papagiannakopoulos+T%22">Papagiannakopoulos T</searchLink>; Department of Pathology, NYU Langone Health, New York, New York.; Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.<br /><searchLink fieldCode="AU" term="%22Der+CJ%22">Der CJ</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101680187%22">BioRxiv : the preprint server for biology</searchLink> [bioRxiv] 2026 Apr 21. <i>Date of Electronic Publication: </i>2026 Apr 21. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Preprint – Name: TitleSource Label: Journal Info Group: Src Data: <i>Country of Publication: </i>United States <i>NLM ID: </i>101680187 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2692-8205 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226928205%22">26928205 </searchLink><i>NLM ISO Abbreviation: </i>bioRxiv <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42079131 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.64898/2026.04.18.719329 Languages: – Code: eng Text: English Titles: – TitleFull: Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chang WH – PersonEntity: Name: NameFull: Vaughan AJ – PersonEntity: Name: NameFull: Stamey AG – PersonEntity: Name: NameFull: Mancini M – PersonEntity: Name: NameFull: Hayashi M – PersonEntity: Name: NameFull: Yang R – PersonEntity: Name: NameFull: Robb R – PersonEntity: Name: NameFull: Andrussier D – PersonEntity: Name: NameFull: Klomp JA – PersonEntity: Name: NameFull: Waters AM – PersonEntity: Name: NameFull: Schaefer A – PersonEntity: Name: NameFull: Wolpin BM – PersonEntity: Name: NameFull: Bryant KL – PersonEntity: Name: NameFull: Cox AD – PersonEntity: Name: NameFull: Simabuco FM – PersonEntity: Name: NameFull: Wong KK – PersonEntity: Name: NameFull: Aguirre AJ – PersonEntity: Name: NameFull: Stalnecker CA – PersonEntity: Name: NameFull: Papagiannakopoulos T – PersonEntity: Name: NameFull: Der CJ IsPartOfRelationships: – BibEntity: Dates: – D: 21 M: 04 Text: 2026 Apr 21 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2692-8205 Titles: – TitleFull: BioRxiv : the preprint server for biology Type: main |
| ResultId | 1 |